Shaniqua J. Anum, Julie Kanter/ scholars.uab.edu
Aug 23, 2026, 14:10
Intravenous Arginine Fails to Reduce Acute Sickle Cell Pain – JAMA
JAMA shared a post on LinkedIn about a recent article by Shaniqua J. Anum and Julie Kanter, adding:
”Acute pain episodes in Sickle Cell Disease remain a leading cause of emergency department visits and hospitalization, yet treatment still relies largely on opioids, nonsteroidal anti-inflammatory drugs, and intravenous fluids.
The STArT trial of intravenous Arginine found no overall benefit vs placebo, and heterogeneity in acute pain mechanisms and trial end points may have limited detection of a vascular-targeted treatment effect.”
Title: Arginine Treatment and Sickle Cell Disease Pain — A Great STArT, but a Hard End Point
Authors: Shaniqua J. Anum, Julie Kanter

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 21, 2026, 03:45Aref Ghanaatpisheh: The Role of Systemic Inflammation in Preoperative Deep Vein Thrombosis Risk Assessment
-
Nov 21, 2026, 03:43Dimitrios Hatzichristou: Advancing Standardization and Quality Control in Platelet-Rich Plasma Therapy
-
Nov 21, 2026, 03:15Amirabbas Sheykhalo: Silent Mesenteric Ischemia in Portomesenteric Thrombosis
-
Nov 21, 2026, 02:51Ivone Su: Raising Awareness of Venous Thromboembolism
-
Nov 21, 2026, 02:40Aniqa Gohar: One Heart Conclave – Advancing Integrated Thrombosis Care
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan